- Home
- / Verrica Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Verrica Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.7
2024-10-29
Market Capitalization
$71.7 M
2024-10-29
Revenue
$35.6 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.0M | 9.0M | 5.1M | 7.6M | 35.6M | |||
| Cost of goods sold | 500.0K | 2.6M | ||||||
| Gross profit | 4.6M | 5.0M | ||||||
| Gross profit margin, % | 90.2% | 65.6% | ||||||
| General and administrative expense | 9.1M | 14.6M | 24.5M | 27.0M | 17.4M | 47.3M | 58.8M | 35.2M |
| Operating expense total | 21.9M | 30.1M | 40.2M | 29.6M | 70.4M | 70.9M | 44.1M | |
| EBIT | (21.9M) | (30.1M) | (40.2M) | (30.9M) | (21.3M) | (65.8M) | (65.9M) | (12.2M) |
| EBIT margin, % | -235.8% | -1283.4% | -871.3% | -34.2% | ||||
| Interest income | 1.2M | 1.9M | 521.0K | 123.0K | 476.0K | 2.7M | 1.4M | 929.0K |
| Interest expense | 1.2M | 4.0M | 7.2M | |||||
| Income tax expense | (2.4M) | (2.4M) | ||||||
| Net Income | (20.6M) | (28.2M) | (42.7M) | (35.1M) | (24.5M) | (67.0M) | (76.6M) | (17.9M) |
| EPS | (0.7) | (1.5) | (1.5) | (1.7) |